(Q37176534)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510534%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510534%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510534%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

S W Pipe

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510534%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

M Jacquemin

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510534%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510534%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510534%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

14 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510534%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

138-146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510534%20AND%20SRC:MED&resulttype=core&format=json

Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Mutating factor VIII: lessons from structure to function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

The tertiary structure and domain organization of coagulation factor VIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Inhibitor development in correlation to factor VIII genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Analysis of factor VIII inhibitors in a haemophilia A patient with an Arg593-->Cys mutation using phage display.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

A Tyr346-->Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Hemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954-->Leu substitution in the factor VIII A3 domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Structure of the C2 domain of human factor VIII at 1.5 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Crystal structures of the membrane-binding C2 domain of human coagulation factor V

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Surface-exposed hemophilic mutations across the factor VIII C2 domain have variable effects on stability and binding activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Detection of three novel mutations in two haemophilia A patients by rapid screening of whole essential region of factor VIII gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

The identification and classification of 41 novel mutations in the factor VIII gene (F8C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Environmental and genetic factors influencing inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

The danger model: a renewed sense of self

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618-->Ser mutation responsive to immune tolerance induction and cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Effective and safe use of recombinant factor VIIa (NovoSeven) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X

Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01730.X